Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study ; volume:22 ; number:1 ; day:22 ; month:5 ; year:2024 ; pages:1-8 ; date:12.2024
Thrombosis journal ; 22, Heft 1 (22.5.2024), 1-8, 12.2024
- Creator
-
Sulaiman, Khalid Al
Aljuhani, Ohoud
Alkofide, Hadeel
Aljohani, Manal A.
Badreldin, Hisham A.
Al Harbi, Mahasen
Aquil, Ghalia
Alhajaji, Raghad
Alqahtani, Rahaf A.
Babonji, Alaa
Altuwayr, Maha
Alshehri, Asma A.
Alfaifi, Mashael
Alharthi, Abdullah F.
Alzahrani, Mohammed
Al Sulaiman, Tareq
Alqahtani, Nasser
Alshahrani, Walaa A.
Al Katheri, Abdulmalik
Albekairy, Abdulkareem M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12959-024-00613-8
- URN
-
urn:nbn:de:101:1-2408011341589.941429144779
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sulaiman, Khalid Al
- Aljuhani, Ohoud
- Alkofide, Hadeel
- Aljohani, Manal A.
- Badreldin, Hisham A.
- Al Harbi, Mahasen
- Aquil, Ghalia
- Alhajaji, Raghad
- Alqahtani, Rahaf A.
- Babonji, Alaa
- Altuwayr, Maha
- Alshehri, Asma A.
- Alfaifi, Mashael
- Alharthi, Abdullah F.
- Alzahrani, Mohammed
- Al Sulaiman, Tareq
- Alqahtani, Nasser
- Alshahrani, Walaa A.
- Al Katheri, Abdulmalik
- Albekairy, Abdulkareem M.
- SpringerLink (Online service)
Other Objects (12)
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
Initial apixaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?
Anticoagulation for non-valvular atrial aibrillation – towards a new beginning with ximelagatran
Non-valvular left ventricular papillary fibroelastoma in a patient with recurrent stroke
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice : A propensity-matched analysis of 76,940 patients
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
Initial apixaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?
Anticoagulation for non-valvular atrial aibrillation – towards a new beginning with ximelagatran
Non-valvular left ventricular papillary fibroelastoma in a patient with recurrent stroke
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice : A propensity-matched analysis of 76,940 patients
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
Initial apixaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?
Anticoagulation for non-valvular atrial aibrillation – towards a new beginning with ximelagatran
Non-valvular left ventricular papillary fibroelastoma in a patient with recurrent stroke